HOME CONTACT ABOUT PRODUCT PIPELINE RESOURCES PARTNERING INVESTORS MEDIA CAREERS Peer Reviewed Publications Parkinson’s Disease Psychosis – Pimavanserin Patel N, Lewitt PA, Neikrug AB, Kesslak P, Coate B, Ancoli-Israel S. Nighttime sleep and daytime sleepiness improved with pimavanserin during treatment of Parkinson’s disease psychosis. Clin Neuropharmacol. 2018;41(6)210-215. Espay AJ, Guskey MT, Norton JC, et al. Pimavanserin for Parkinson’s disease psychosis: effects stratified by baseline cognition and use of cognitive-enhancing medications. Mov Disord. 2018;33(11):1769-1776. Citrome L, Norton JC, Chi-Burris K, Demos G. Pimavanserin for the treatment of Parkinson’s disease psychosis: number needed to treat, number needed to harm, and likelihood to be helped or harmed. CNS Spectr. 2018;23(3):228-238. Cummings J, Isaacson S, Mills R, et al. Pimavanserin for patients with Parkinson’s disease psychosis: a randomised, placebo-controlled phase 3 trial. Lancet. 2014;383(9916):533-540. Voss T, Bahr D, Cummings J, Mills R, Ravina B, Williams H. Performance of a shortened Scale for Assessment of Positive Symptoms for Parkinson’s disease psychosis. Parkinsonism Relat Disord. 2013;19(3):295-299. Meltzer HY, Mills R, Revell S, et al. Pimavanserin, a serotonin2a receptor inverse agonist, for the treatment of Parkinson’s disease psychosis. Neuropsychopharmacology. 2010;35(4):881–892. Investigational – Pimavanserin Dementia-Related Psychosis Ballard C, Youakim JM, Coate B, Stankovic S. Pimavanserin in Alzheimer’s disease psychosis: efficacy in patients with more pronounced psychotic symptoms. J Prev Alzheimer Dis. 2019;(6)1:27-33. Cummings C, Ballard C, Tariot P, et al. Pimavanserin: potential treatment for dementia related-psychosis. J Prev Alzheimer Dis. 2018;5(4):253-258. Ballard C, Banister C, Khan Z, et al. Evaluation of the safety, tolerability, and efficacy of pimavanserin versus placebo in patients with Alzheimer’s disease psychosis: a phase 2, randomised, placebo-controlled, double-blind study. Lancet Neurol. 2018;17(3):213-222. Schizophrenia Meltzer HY, Elkis H, Vanover K, et al. Pimavanserin, a selective serotonin (5-HT)2A-inverse agonist, enhances the efficacy and safety of risperidone, 2mg/day, but does not enhance efficacy of haloperidol, 2mg/day: comparison with reference dose risperidone, 6mg/day. Schizophr Res. 2012;141(2-3):144-152. General – Pimavanserin Hacksell U, Burstein ES, McFarland K, Mills RG, Williams H. On the discovery and development of pimavanserin: a novel drug candidate for Parkinson’s psychosis. Neurochem Res. 2014;39(10):2008-2017. Rett Syndrome – Trofinetide Glaze DG, Neul JL, Kaufmann WE, et al. Double-blind, randomized, placebo-controlled study of trofinetide in pediatric Rett syndrome. Neurology. 2019;92(16):e1912-e1925. Glaze DG, Neul JL, Percy A, et al. A double-blind, randomized, placebo-controlled clinical study of trofinetide in the treatment of Rett syndrome. Pediatr Neurol. 2017;76:37-46. Neul JL, Glaze DG, Percy AK, et al. Improving treatment trial outcomes for Rett syndrome: the development of Rett-specific anchors for the Clinical Global Impression scale. J Child Neurol. 2015;30(13):1743-1748. General – Trofinetide Vahdatpour C, Dyer AH, Tropea D. Insulin-like growth factor 1 and related compounds in the treatment of childhood-onset neurodevelopmental disorders. Front Neurosci. 2016;10:450. Deacon RM, Glass L, Snape M, et al. NNZ-2566, a novel analog of (1-3) IGF-1, as a potential therapeutic agent for fragile X syndrome. Neuromolecular Med. 2015;17(1):71-82. Corvin AP, Molinos I, Little G, et al. Insulin-like growth factor 1 (IGF1) and its active peptide (1-3)IGF1 enhance the expression of synaptic markers in neuronal circuits through different cellular mechanisms. Neurosci Lett. 2012;520(1):51-56. Tropea D, Giacometti E, Wilson NR, et al. Partial reversal of Rett Syndrome-like symptoms in MeCP2 mutant mice. Proc Natl Acad Sci U S A. 2009;106(6):2029-2034. RESOURCES PARKINSON’S DISEASE PSYCHOSIS CLINICAL TRIALS INVESTIGATOR INITIATED STUDIES MEDICAL EDUCATION GRANTS SCIENTIFIC PUBLICATIONS COMPLIANCE Print page Share PRIVACY COOKIES PRIVACY SHIELD TERMS EMAIL © 2021 Acadia Pharmaceuticals Inc. Acadia and NUPLAZID are registered trademarks of Acadia Pharmaceuticals Inc. All rights reserved. By using this website without changing your cookie settings in your browser, you agree to our use of cookies. For further details on cookies, how we use cookies and how to delete or block the use of cookies, please read our .